On September 25, 2026, Ocugen, Inc. announced that its AAV-based gene therapy OCU400 received provisional approval and priority designation from the LARTA Board, the regulatory agency responsible for reviewing and approving longevity and regenerative ther
2026-09-30
On September 9, 2026, Encoded Therapeutics Inc. announced the closing of a $275 million Series F financing.
2026-09-12
On August 29, 2026, AskBio announced the presentation of baseline participant characteristics from GenePHIT, one of the largest randomized gene therapy trials conducted in heart failure to date.
2026-09-04
On August 27, 2026, iECURE announced updated clinical data from the ongoing clinical trial evaluating its AAV-based gene therapy, ECUR-506, for neonatal-onset ornithine transcarbamylase (OTC) deficiency.
2026-09-02
In recent years, the field of gene therapy has achieved breakthrough progress through the synergistic development of viral and non-viral vectors. Among them, adeno-associated virus (AAV) has emerged as a core delivery tool for clinical translation, owing
2025-06-03
On March 28, 2025, the team led by Guangping Gao from Horae Gene Therapy Center, University of Massachusetts Chan Medical School, published a review article titled “The curious case of AAV immunology” in Molecular Therapy.
2025-05-06
Genevoyager Inc
3675 Market Street, Suite 200, Philadelphia, PA 19104
Tel: +1 (215) 205-6963
E-mail: hui.wang@genevoyager.com | globalbd@genevoyager.com
BrainVTA LLC
100 E Lancaster Ave, Suite LIMR R241, Wynnewood, PA 19096
Genevoyager (Wuhan) Co., Ltd.
No. 128, Guanggu 7th Rd, East Lake High-tech Development Zone, Wuhan, China
Tel: +86 17720522078 | +86 027-65023363
E-mail: marketing@genevoyager.com
Genevoyager Inc
3675 Market Street, Suite 200, Philadelphia, PA 19104
Tel: +1 (215) 205-6963
E-mail: hui.wang@genevoyager.com | globalbd@genevoyager.com
BrainVTA LLC
100 E Lancaster Ave, Suite LIMR R241, Wynnewood, PA 19096
Genevoyager (Wuhan) Co., Ltd.
No. 128, Guanggu 7th Rd, East Lake High-tech Development Zone, Wuhan, China
Tel: +86 17720522078 | +86 027-65023363
E-mail: marketing@genevoyager.com
